1. Home
  2. CINGW vs ZTO Comparison

CINGW vs ZTO Comparison

Compare CINGW & ZTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • ZTO
  • Stock Information
  • Founded
  • CINGW N/A
  • ZTO 2002
  • Country
  • CINGW United States
  • ZTO China
  • Employees
  • CINGW 13
  • ZTO N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • ZTO Advertising
  • Sector
  • CINGW Health Care
  • ZTO Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • ZTO Nasdaq
  • Market Cap
  • CINGW N/A
  • ZTO N/A
  • IPO Year
  • CINGW 2021
  • ZTO 2016
  • Fundamental
  • Price
  • CINGW $0.03
  • ZTO $19.07
  • Analyst Decision
  • CINGW
  • ZTO Buy
  • Analyst Count
  • CINGW 0
  • ZTO 4
  • Target Price
  • CINGW N/A
  • ZTO $25.13
  • AVG Volume (30 Days)
  • CINGW N/A
  • ZTO 2.9M
  • Earning Date
  • CINGW N/A
  • ZTO 05-14-2025
  • Dividend Yield
  • CINGW N/A
  • ZTO 3.61%
  • EPS Growth
  • CINGW N/A
  • ZTO N/A
  • EPS
  • CINGW N/A
  • ZTO 1.12
  • Revenue
  • CINGW N/A
  • ZTO $6,066,599,984.00
  • Revenue This Year
  • CINGW N/A
  • ZTO $9.23
  • Revenue Next Year
  • CINGW N/A
  • ZTO $10.36
  • P/E Ratio
  • CINGW N/A
  • ZTO $17.03
  • Revenue Growth
  • CINGW N/A
  • ZTO 15.26
  • 52 Week Low
  • CINGW N/A
  • ZTO $16.34
  • 52 Week High
  • CINGW N/A
  • ZTO $27.50
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • ZTO 50.52
  • Support Level
  • CINGW N/A
  • ZTO $18.48
  • Resistance Level
  • CINGW N/A
  • ZTO $19.67
  • Average True Range (ATR)
  • CINGW 0.00
  • ZTO 0.81
  • MACD
  • CINGW 0.00
  • ZTO 0.12
  • Stochastic Oscillator
  • CINGW 0.00
  • ZTO 81.98

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: